Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Toshirou NishidaShinsuke SatoMasato OzakaYujiro NakaharaYoshito KomatsuMasato KondoHaruhiko ChoSeiichi HirotaTatsuo KagimuraYukinori KurokawaYuko Kitagawanull nullPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2022)
The recurrence risk of high-risk GISTs after adjuvant therapy is similar irrespective of the adjuvant duration and imatinib adjuvant may not cure but may delay recurrence. RFS after long-term adjuvant therapy appeared better than that after 3-year adjuvant.
Keyphrases